FAMy Study BMS CA054-010 https://www.nct-dresden.de/en/trials/900-000002295 https://www.nct-dresden.de/@@site-logo/logo-nct.svg FAMy Study BMS CA054-010 Category Hematological neoplasms Subcategory Other indications (e.g. myeloproliferative diseases) Trial Type First-Line-Therapy (Metastatic Disease/Hematology) Description for experts Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis. Description for laymen Fedratinib in Combination with CC-486, a Hypomethylating Agent, in Patients with Accelerated Phase Myelofibrosis.
